Levodopa

Generic Name
Levodopa
Brand Names
Dhivy, Duodopa, Duopa, Inbrija, Parcopa, Prolopa, Rytary, Sinemet, Stalevo
Drug Type
Small Molecule
Chemical Formula
C9H11NO4
CAS Number
59-92-7
Unique Ingredient Identifier
46627O600J
Background

Levodopa is a prodrug of dopamine that is administered to patients with Parkinson's due to its ability to cross the blood-brain barrier. Levodopa can be metabolised to dopamine on either side of the blood-brain barrier and so it is generally administered with a dopa decarboxylase inhibitor like carbidopa to prevent metabolism until after it has crossed the b...

Indication

Levodopa on its own is formulated as an oral inhalation powder indicated for intermittent treatment of off episodes in Parkinson's patients who are already being treated with carbidopa and levodopa. Levodopa is most commonly formulated as an oral tablet with a peripheral dopa decarboxylase inhibitor indicated for treatment of Parkinson's disease, post-enceph...

Associated Conditions
Paralysis agitans, Parkinson's Disease (PD), Parkinsonism, Parkinsonism post encephalitic, Restless Legs Syndrome (RLS), Advanced Motor fluctuations
Associated Therapies
-
Clinical Trials
Related News
news-medical.net
·

Collaborative study investigates underlying cause of neuropsychiatric symptoms in ...

Parkinson's disease patients often experience neuropsychiatric symptoms like cognitive issues, depression, and anxiety. A research team, including Binghamton University's Christopher R. Bishop, received a $3 million grant from the Department of Defense to study these symptoms. Their focus is on how serotonin-producing neurons, which can produce dopamine, contribute to these issues. The team aims to improve PD symptom management and has identified potential repurposed medications.
eurekalert.org
·

Department of Defense-funded research may lead to new treatments for Parkinson’s disease

Binghamton University Psychology Professor Christopher R. Bishop leads a $3 million, four-year DOD-funded study on neuropsychiatric symptoms in Parkinson’s disease, involving researchers from Binghamton, Barrow Neurological Institute, and the University of Illinois. The study focuses on serotonin neurons producing dopamine, causing side effects, and aims to improve PD patient lives through new treatments and clinical trials.
drugs.com
·

Enrollment Completed for Phase 2 Clinical Trial Evaluating VG081821AC for the Treatment of Parkinson's Disease

Vimgreen Pharmaceuticals completed enrollment for its Phase 2 trial of VG081821AC, an A2A receptor antagonist for early-to-mid stage Parkinson's disease, with 150 participants. The trial aims to assess VG081821's safety and efficacy as monotherapy, potentially offering a non-dopaminergic treatment option to avoid motor complications associated with long-term L-Dopa use.
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy